Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • AbCellera, Merck deal

    AbCellera Biologics Inc., Vancouver, B.C. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Antibodies AbCellera and Merck will use AbCelleras microfluidic discovery technology to discover mAbs against an …

    Published on 2/8/2016
  • Abzena deal

    Abzena plc (LSE:ABZA), Babraham, U.K. Business: Cancer Abzena granted an undisclosed U.S. cancer company non-exclusive rights to use Abzenas ThioBridge antibody drug conjugate (ADC) linker technology for up to three …

    Published on 2/8/2016
  • Acerta Pharma, AstraZeneca deal

    Acerta Pharma B.V., Oss, the Netherlands AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer AstraZeneca completed its acquisition of a 55% stake in Acerta for $2.5 billion in cash. Acerta will also …

    Published on 2/8/2016
  • Acorda, Endo deal

    Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Autoimmune Acorda granted Endos Par Pharmaceutical Inc. company rights to market a generic …

    Published on 2/8/2016
  • Adaptimmune, GlaxoSmithKline deal

    Adaptimmune Ltd., Abingdon, U.K. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Cancer, Gene/Cell therapy Adaptimmune and GlaxoSmithKline expanded a 2014 deal to co-develop autologous T cell receptor (…

    Published on 2/8/2016
  • Alere, Abbott deal

    Alere Inc. (NYSE:ALR), Waltham, Mass. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Business: Diagnostic Abbott will acquire diagnostics company Alere for $56 per share in cash, or about $5.8 billion. The price is a…

    Published on 2/8/2016
  • Annapurna Therapeutics, Avalanche Biotechnologies deal

    Annapurna Therapeutics S.A.S., Paris, France Avalanche Biotechnologies Inc. (NASDAQ:AAVL), Menlo Park, Calif. Business: Neurology, Endocrine/Metabolic, Inflammation Avalanche will acquire Annapurna, gaining four …

    Published on 2/8/2016
  • Applied Immune Technologies, Adicet deal

    Applied Immune Technologies Ltd., Technion City, Israel Adicet Bio Inc., Menlo Park, Calif. Business: Diagnostic, Antibodies Adicet acquired Applied Immune Technologies, which develops T cell receptor-like antibodies …

    Published on 2/8/2016
  • AstraZeneca, Allergan deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Infectious The companies partnered to develop and commercialize ATM-AVI to treat metallo-beta-lactamase-producing Gram-…

    Published on 2/8/2016
  • Biotest, Kedrion deal

    Biotest AG (Xetra:BIO), Dreieich, Germany Kedrion Group S.p.A., Barga, Italy Business: Autoimmune Biotest granted Kedrion exclusive rights to commercialize Bivigam in the U.S. The polyspecific IV immune globulin is …

    Published on 2/8/2016
  • Bioventix, CardiNor deal

    Bioventix plc (LSE:BVXP), Farnham, U.K. CardiNor A/S, Oslo, Norway Business: Diagnostic, Antibodies Bioventix will develop and provide antibodies for CardiNors Secretoneurin in vitro diagnostic (IVD) test. Secretoneurin…

    Published on 2/8/2016
  • Bristol-Myers, Pfizer, Portola deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Pfizer Inc. (NYSE:PFE), New York, N.Y. Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Business: Hematology Portola granted Pfizer and Bristol-…

    Published on 2/8/2016
  • Cevec, Beckman Research Institute deal

    Cevec Pharmaceuticals GmbH, Cologne, Germany Beckman Research Institute of City of Hope, Duarte, Calif. Business: Gene/Cell therapy Cevec granted the institute non-exclusive, worldwide rights to lentiviral and …

    Published on 2/8/2016
  • Clino, Astellas deal

    Clino Ltd., Sendai, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Ophthalmic Clino granted Astellas worldwide rights to develop and commercialize adeno-associated virus (AAV)-modified Volvox …

    Published on 2/8/2016
  • Eleven Biotherapeutics, Albumedix deal

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Albumedix A/S, Bagsvaerd, Denmark Business: Drug delivery Albumedix acquired Elevens Supermin albumin variant technology. Eleven will receive an undisclosed …

    Published on 2/8/2016
  • Eli Lilly, Roche deal

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Lilly and Roche partnered non-exclusively to develop a cerebrospinal fluid (CSF) assay for Alzheimers…

    Published on 2/8/2016
  • Ferring, Karolinska Institute deal

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Karolinska Institute, Stockholm, Sweden Business: Pharmaceuticals Ferring and Karolinska partnered to establish a research center exploring the human microbiome in …

    Published on 2/8/2016
  • GeneOne, Inovio deal

    GeneOne Life Science Inc. (KSE:011000), Seoul, South Korea Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Business: Infectious The companies partnered to develop a DNA vaccine to prevent and treat Zika virus …

    Published on 2/8/2016
  • Huya, Eisai deal

    Huya Bioscience International LLC, San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Huya granted Eisai exclusive rights to develop and commercialize HBI-8000 for cancer indications in Japan, …

    Published on 2/8/2016
  • MannKind, Receptor Life Sciences deal

    MannKind Corp. (NASDAQ:MNKD;Tel Aviv:MNKD), Valencia, Calif. Receptor Life Sciences Inc., Seattle, Wash. Business: Neurology, Drug delivery, Inflammation MannKind granted newco Receptor Life Sciences a license to …

    Published on 2/8/2016
  • Medicines Co., Mallinckrodt deal

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Business: Hematology The Medicines Co. divested its hemostasis portfolio to Mallinckrodt for $174 million up front and up to…

    Published on 2/8/2016
  • Mersana, Takeda deal

    Mersana Therapeutics Inc., Cambridge, Mass. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer Mersana granted Takeda exclusive rights to co-develop and commercialize XMT-1522. Mersana expects to…

    Published on 2/8/2016
  • Mersana, Takeda deal

    Mersana Therapeutics Inc., Cambridge, Mass. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer Mersana and Takeda expanded their 2014 deal to create antibody-drug conjugates (ADCs) comprised of …

    Published on 2/8/2016
  • Portola, Bayer deal

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San Francisco, Calif. Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Hematology Portola partnered with Bayer to include Bayers Xarelto rivaroxaban in Japanese …

    Published on 2/8/2016
  • Saniona, Upsher-Smith deal

    Saniona AB (AktieTorget:SANION), Ballerup, Denmark Upsher-Smith Laboratories Inc., Maple Grove, Minn. Business: Neurology Upsher-Smiths Proximagen Ltd. subsidiary and Saniona partnered to discover small molecule …

    Published on 2/8/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993